S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.
Caroline S. Fox,Sherita Hill Golden,Cheryl A.M. Anderson,George A. Bray,Lora E. Burke,Ian H. de Boer,Prakash Deedwania,Robert H. Eckel,Abby G. Ershow,Judith E. Fradkin,Silvio E. Inzucchi,Mikhail Kosiborod,Robert G. Nelson,Mahesh J. Patel,Michael Pignone,Laurie Quinn,Philip R. Schauer,Elizabeth Selvin,Dorothea K. Vafiadis +18 more
TL;DR: A synthesis of the recent literature, new guidelines, and clinical targets, including screening for kidney and subclinical cardiovascular disease for the contemporary management of patients with type 2 diabetes mellitus are presented.
Journal ArticleDOI
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z.I. Cherney,David Z.I. Cherney,Bernard Zinman,Silvio E. Inzucchi,Audrey Koitka-Weber,Michaela Mattheus,Maximilian von Eynatten,Christoph Wanner +7 more
TL;DR: In this article, the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established cardiovascular disease were investigated.
Journal ArticleDOI
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
David G. Maggs,Thomas A. Buchanan,Charles F. Burant,Gary W. Cline,Barry Gumbiner,Willa A. Hsueh,Silvio E. Inzucchi,David E. Kelley,John J. Nolan,Jerrold M. Olefsky,Kenneth S. Polonsky,David Silver,Thomas R. Valiquett,Gerald I. Shulman +13 more
TL;DR: Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus as mentioned in this paper, which is unknown mechanism by which it exerts its effect on systemic glucose metabolism.
Journal ArticleDOI
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
William T. Cefalu,Sanjay Kaul,Hertzel C. Gerstein,Rury R. Holman,Bernard Zinman,Jay S. Skyler,Jennifer B. Green,John B. Buse,Silvio E. Inzucchi,Lawrence A. Leiter,Itamar Raz,Julio Rosenstock,Matthew C. Riddle +12 more
TL;DR: A review of the long-term cardiovascular outcomes trials (CVOTs) can be found in this article, where the authors discuss the benefits and limitations of current designs, discuss the merits of modifications that might improve the efficiency and clinical value of future trials.
Journal ArticleDOI
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation
Michael Pignone,Mark J. Alberts,John A. Colwell,Mary Cushman,Silvio E. Inzucchi,Debabrata Mukherjee,Robert S. Rosenson,Craig D. Williams,Peter W. F. Wilson,M. Sue Kirkman +9 more
TL;DR: Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk patients with myocardial infarction (MI) or stroke (secondary prevention), and its net benefit among patients with no previous cardiovascular events is more controversial.